Modulation of redox-sensitive proteins (peroxiredoxin 3/5, PRX3/PRX5, selenoenzyme 2, TR2, glutathione reductase, GR, and NADPH oxidase 4, NOX4) is suggested as a target for cancer therapy due to their metabolic role in various stages of melanoma, from initiation to metastasis and resistance [40]. Here, NOX4 is linked to melanoma.